Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Park, Se Hoon ^a   Lee, Yuna ^a   Han, Sang Hoon ^a   Kwon, So Young ^a   Kwon, Oh Sang ^a   Kim, Sun Suk ^a   Kim, Ju Hyun ^a   Park, Yeon Ho ^a   Lee, Jeong Nam ^a   Bang, Soo Mee ^a   Cho, Eun Kyung ^a   Shin, Dong Bok ^a   Lee, Jae Hoon ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DOXORUBICIN; HEMOPOIETIC GROWTH FACTOR; LAMIVUDINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL;

ADULT; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; METASTASIS; NAUSEA; PATIENT CODING; PERFORMANCE; SERODIAGNOSIS; CLINICAL TRIAL; LIVER TUMOR; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 30544447796     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-3     Document Type: Article

References (31)

1. Bae JM, Won YJ, Jung KW, Park JG: Annual report of the Korean central cancer registry program 2000. Cancer Res Treat 2002, 34:77-83.
2. Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, Khayat D, Opolon P, Poynard T: Review article: Overview of medical treatments in unresectable hepatocellular carcinoma-an impossible meta-analysis? Aliment Pharmacol Ther 1998, 12(2):111-126.
3. Simonetti RG, Liberati A, Angiolini C, Pagliaro L: Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997, 8(2):117-136.
4. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ: Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988, 62(3):479-483.
5. Lin DY, Lin SM, Liaw YF: Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997, 12(9-10):S319-328.
6. Friedman MA: Primary hepatocellular cancer - present results and future prospects. Int J Radiat Oncol Biol Phys 1983, 9(12):1841-1850.
7. Falkson G, Ryan LM, Johnson LA, Simson IW, Coetzer BJ, Carbone PP, Creech RH, Schutt AJ: A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 1987, 60(9):2141-2145.
8. Ellis PA, Norman A, Hill A, O'Brien ME, Nicolson M, Hickish T, Cunningham D: Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 1995, 31A(10):1594-1598.
9. Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, Mok TS, Yeo W, Liew CT, Leung NW, Tang AM, Johnson PJ: Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999, 5(7):1676-1681.
10. Lee JA, Kang YK, Kim CM, Lee JO, Kang TW: A phase II study of AP (doxorubicin, cisplatin) chemotherapy in patients with advanced hepatocellular carcinoma. J Korean Cancer Assoc 1997, 29(1):103-110.
11. Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Joh J, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K: Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004, 54(5):385-390.
12. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998, 34(8):1274-1281.
13. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000, 45(4):291-297.
14. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P: Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002, 38(3):349-358.
15. Twelves C, Glynne-Jones R, Cassidy J, Schuller J, Goggin T, Roos B, Banken L, Utoh M, Weidekamm E, Reigner B: Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999, 5(7):1696-1702.
16. Desmet VJ, Gerber M, Hoofnagle JH, Manus M, Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994, 19(6):1513-1520.
17. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10(1):1-10.
18. Nzeako UC, Goodman ZD, Ishak KG: Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol 1996, 105(1):65-75.
19. Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, Block JB, Tong M, Chan KK: Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 1984, 68(3):487-491.
20. Boucher E, Corbinais S, Brissot P, Boudjema K, Raoul JL: Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 2002, 50(4):305-308.
21. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002, 13(4):566-575.
22. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001, 19(21):4097-4106
23. Hoff PM, Ansari R, Batits G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001, 19(8)2282-2292.
24. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer, II, Wolff RA, Charnsangavej C, Brown TD: Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004, 101(3):578-586.
25. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2004, 97(20):1532-1538.
26. Nowak AK, Chow PK, Findlay M: Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004, 40(10):1474-1484.
27. Jiang W, Lu Z, He Y, Diasio RB: Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 1997, 3(3):395-399.
28. Chenivese X, Franco D, Brechot C: MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis. J Hepatol 1993, 18(2):168-172.
29. Abou-Alfa GK: Current and novel therapeutics for hepatocellular carcinoma. In: The 40th Am Soc Clin Oncol Education Book 2004:192-197.
30. Hegewisch-Becker S, Sterneck M, Schubert U, Rogiers X, Guerciolini R, Pierce JE, Hossfeld DK: Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2004, 22:4089a.
31. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic application. Blood 2003, 101(6):2377-2380.